✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Seviteronel is an investigational drug.
There have been 6 clinical trials for Seviteronel. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2015.
The most common disease conditions in clinical trials are Triple Negative Breast Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Innocrin Pharmaceutical, St Vincent's Hospital, Sydney, and National Cancer Institute (NCI).
Recent Clinical Trials for Seviteronel
|Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer||St Vincent's Hospital, Sydney||Phase 1/Phase 2|
|Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma||St Vincent's Hospital, Sydney||Phase 2|
|CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)||Innocrin Pharmaceutical||Phase 1/Phase 2|